Table 2.

Summary of findings from the experimental human studies.

Author and Reference	Year	Patients Enrolled (N)	Experimental Treatment	Parameters Tested	Tissue Samples	Method	Results
Chang et al. [96]	2016	children and adolescent with AD, moderate SCORAD (38)	exogenous MT given 3 mg/day for 4 weeks before bedtime	MT, sleep, IgE, SCORAD	urine	ELISA (MT), actigraphy	MT application reduced SCORAD, decreased sleep onset latency; improvement of sleep was not correlated with SCORAD; serum IgE was similar to control
Ardakani et al. [97]	2018	children with AD, moderate and severe SCORAD (35)	exogenous MT given 6 mg/day for 6 weeks before bedtime	SCORAD, sleep, CRP, IgE	blood	SCORAD, sleep questionnaire	MT application reduced SCORAD, and IgE, improved total sleep scores; CRP and pruritus were similar to control